Evidence mapPaperPMID 39572234Full record

ReviewGenes & development2025

mTORC1, the maestro of cell metabolism and growth.

Long He, Sungyun Cho, John Blenis

Abstract readReview
In one paragraph

Review in Genes & development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Tuberous sclerosis complex.Nature reviews. Disease primers · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Long He *Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA; jblenis@med.cornell.edu loh2007@med.cornell.edu.ORCID 0000-0003-4721-9221
Sungyun Cho *Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0009-0009-2690-2268
John BlenisMeyer Cancer Center, Weill Cornell Medicine, New York, New York 10021, USA; jblenis@med.cornell.edu loh2007@med.cornell.edu.ORCID 0000-0003-3622-2337

Funding

SIGNAL TRANSDUCTION TO PP70 S6KR01GM051405 · HARVARD UNIVERSITY (MEDICAL SCHOOL) · 1995 to 2005
$3.0M
ONCOGENIC REGULATION OF S6 PROTEIN KINASE &CELL GROWTHR01CA046595 · WEILL MEDICAL COLL OF CORNELL UNIV · 1988 to 2025
$2.1M
Propionate metabolism and cancerR01CA273357 · WEILL MEDICAL COLL OF CORNELL UNIV · 2025 to 2025
$634k
NCI NIH HHS R01 CA046595NCI NIH HHS R01 CA273357NIGMS NIH HHS R01 GM051405
6 · The paper itself

Abstract

The mechanistic target of rapamycin (mTOR) pathway senses and integrates various environmental and intracellular cues to regulate cell growth and proliferation. As a key conductor of the balance between anabolic and catabolic processes, mTOR complex 1 (mTORC1) orchestrates the symphonic regulation of glycolysis, nucleic acid and lipid metabolism, protein translation and degradation, and gene expression. Dysregulation of the mTOR pathway is linked to numerous human diseases, including cancer, neurodegenerative disorders, obesity, diabetes, and aging. This review provides an in-depth understanding of how nutrients and growth signals are coordinated to influence mTOR signaling and the extensive metabolic rewiring under its command. Additionally, we discuss the use of mTORC1 inhibitors in various aging-associated metabolic diseases and the current and future potential for targeting mTOR in clinical settings. By deciphering the complex landscape of mTORC1 signaling, this review aims to inform novel therapeutic strategies and provide a road map for future research endeavors in this dynamic and rapidly evolving field.

Indexed as

Mechanistic Target of Rapamycin Complex 1Signal TransductionAnimalsCell ProliferationHumansTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1TOR Serine-Threonine Kinasescancercellular signalingmTmTORC1mTOR complex 1

Identifiers

PMID39572234
PMCPMC11789495

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.